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Abstract
Epidermal growth factor receptor (EGFR)–targeting therapeutics have shown efficacy in the treatment of colorectal
cancer patients. Clinical studies have revealed that activating mutations in the KRAS protooncogene predict resis-
tance to EGFR-targeted therapy. However, the causality between mutant KRAS and resistance to EGFR inhibition
has so far not been demonstrated. Here, we show that deletion of the oncogenic KRAS allele from colorectal tumor
cells resensitizes those cells to EGFR inhibitors. Resensitization was accompanied by an acquired dependency on
the EGFR for maintaining basal extracellular signal–regulated kinase (ERK) activity. Deletion of oncogenic KRAS not
only resensitized tumor cells to EGFR inhibition but also promoted EGF-induced NRAS activation, ERK and AKT
phosphorylation, and c-FOS transcription. The poor responsiveness of mutant KRAS tumor cells to EGFR inhibition
and activation was accompanied by a reduced capacity of these cells to bind and internalize EGF and by a failure to
retain EGFR at the plasma membrane. Of 16 human colorectal tumors with activating mutations in KRAS, 15 dis-
played loss of basolateral EGFR localization. Plasma membrane localization of the EGFR could be restored in vitro
by suppressing receptor endocytosis through Rho kinase inhibition. This caused an EGFR-dependent increase in
basal and EGF-stimulated ERK phosphorylation but failed to restore tumor cell sensitivity to EGFR inhibition. Our
results demonstrate a causal role for oncogenic KRAS in desensitizing tumor cells not only to EGFR inhibitors but
also to EGF itself.
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Introduction
The epidermal growth factor receptor (EGFR) is widely expressed in
the gastrointestinal tract and stimulates proliferation of a range of cell
types, including epithelial cells [1]. Most colorectal tumors are initiated
by inactivating mutations in the tumor suppressor gene APC [2]. Loss
of functional APC is sufficient to initiate the formation of intestinal
polyps in mice, and this is accompanied by increased EGFR expression
and activity [3]. Partial loss of EGFR function, or pharmacological in-
hibition of the EGFR, greatly reduces polyp development in this model
[4]. The EGFR is also frequently overexpressed in human colorectal
tumors when compared with normal intestinal tissue, and this is associ-
ated with increased metastatic potential and poor prognosis [5–7].
EGFR-targeting therapeutics have shown promising clinical activity
in a minority of colorectal cancer patients [8–12]. The presence of
activating mutations in the KRAS gene in these tumors is a reliable pre-
dictor of tumor resistance to anti-EGFR therapy [13,14]. Conversely,
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high expression of EGFR ligands predicts response to anti-EGFR ther-
apy but only in the subset of wild-type KRAS tumors [15,16]. Although
these clinical studies have firmly associated activating mutations in
KRAS with resistance to EGFR-targeted therapy, so far, it has not been
demonstrated that signaling by the KRAS oncoprotein is the underlying
cause of resistance to EGFR inhibition. For instance, it is possible that
colorectal tumors with KRAS mutations preferentially develop in an
(epi)genetic background of EGFR independence. Such EGFR inde-
pendence has previously been shown in a minority of tumors that are
driven by APC loss only [4]. Constitutive activation of KRAS and its
downstream signaling pathways may reduce the dependency on up-
stream activators such as the EGFR. However, the EGFR activates
multiple distinct mitogenic signaling pathways of which the GRB2/
SOS/RAS pathway is only one [17]. In addition, activation of the extra-
cellular signal–regulated kinase (ERK) pathway by EGFR ligands is
very different in time and amplitude than activation of this pathway
by a constitutively active endogenous KRAS mutant protein. For these
reasons, we set out to assess the causal relationship between the presence
of endogenous oncogenic KRAS and EGFR independence.
Materials and Methods
Cell Culture
The colorectal cancer cell lines HCT116, CT26, and DLD1 were
purchased from ATCC (Manassas, VA). The HCT116 cells lacking
KRASD13 (HKH2) with their own HCT116 control and the DLD1
cells lacking KRASD13 (DKO4) with their own DLD1 control were
obtained from Dr Shirasawa and were previously described [18]. We
previously established CT26 cell lines in which the endogenous
KrasD12 allele is stably suppressed by mutant-specific RNA interfer-
ence, using a lentiviral vector (CT26-KrasKD) [19]. Control CT26
cells were transduced with a lentiviral short hairpin RNA (shRNA)
construct targeting luciferase (see below). All these cell lines were cul-
tured in Dulbecco’s modified Eagle medium (DMEM; Dulbecco,
ICN Pharmaceuticals, Zoetermeer, The Netherlands) supplemented
with 5% (vol./vol.) fetal calf serum, 2 mM glutamine, 0.1 mg/ml
streptomycin, and 100 U/ml penicillin. L145 cells were derived directly
from a tumor biopsy of a patient operated on for colorectal liver metas-
tases in our hospital. The tissue fragment was washed with PBS and was
mechanically dissociated. Enzymatic digestion (thermolysin [Sigma, St
Louis, MO] 0.05% for 2 hours at 37°C) was performed in DMEM/
F12. Single-cell suspensions were obtained by filtering through a
40-μm-pore size nylon cell strainer (BD Falcon, Breda, The Nether-
lands). Spheroids formed spontaneously by culturing in DMEM/F12
(Gibco, Breda, The Netherlands) supplemented with 0.6% glucose
(BDH Laboratory Supplies, Soulbury, UK), 2 mM L-glutamine (Bio-
whittaker, Walkersville, MD), 9.6 μg/ml putrescin (Sigma), 6.3 ng/ml
progesterone (Sigma), 5.2 ng/ml sodium selenite (Sigma), 25μg/ml insu-
lin (Sigma), 100 μg/ml apotransferrin (Sigma), 5 mMHEPES (Gibco),
0.005 μg/ml trace element A (Cellgro, Manassas, VA), 0.01 μg/ml trace
element B (Cellgro), 0.01 μg/ml trace element C (Cellgro), 100 μM
β-mercaptoethanol (Merck, Schiphol, The Netherlands), 10 ml of
antibiotic-antimycotic (Gibco), 4 μg/ml gentamicin (Invitrogen, Mo-
lecular Probes, Leiden, TheNetherlands), 0.002% lipidmixture (Sigma),
5 μg/ml glutathione (Roche, Woerden, The Netherlands), and 4 μg/ml
heparin (Sigma). The human intestinal epithelial cells (HIECs) were
a kind gift from Dr Beaulieu, and these have been described before
[20]. All cells were kept at 37°C in a humidified atmosphere contain-
ing 5% CO2.
Antibodies and Inhibitors
The following antibodies were from Cell Signaling Technology,
Inc, Leiden, The Netherlands: rabbit anti–phospho–mitogen-activated
protein kinase (MAPK) p44/42 (Thr 202/Tyr 204), rabbit anti–
phopsho-Akt (Ser 473), rabbit anti-EGFR (no. 2232; used for HCT116
and HKH2 cells), and rabbit anti–phospho-EGFR antibodies (Tyr 845,
992, 1068, 1045; nos. 2231, 2234, 2235, and 2237). EGFR phos-
phorylation status was determined by probing the Western blots
with a mixture of antibodies 2231, 2234, 2235, and 2237. For EGFR
detection in mouse CT26 and CT26-KrasKD cells, we used rat anti-
mouse EGFR (clone 176436; R&D Systems, Minneapolis, MN).
Goat anti-Akt1 was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Secondary peroxidase-conjugated antibodies were from
Dako (Glostrup, Denmark).
Gefitinib (Iressa/ZD1839) was kindly provided by AstraZeneca
(Macclesfield, United Kingdom). Cetuximab was kindly provided by
Merck (Darmstadt, Germany). Erlotinib (Tarceva/OSI1774) was pur-
chased from LC Laboratories (Woburn, MA). The MAPK/ERK kinase
(MEK) inhibitor U0126 was from Promega (Madison, WI), the phos-
phatidylinositol-3-kinase (PI3K) inhibitor LY294002 and the Rho
kinase (ROK) inhibitor Y27632 were from Sigma, and the Rac inhibi-
tor (Rac1-Inh) was from Calbiochem (Darmstadt, Germany).
Viability Assay
Cells were plated at a density of 5000 cells/well in DMEM contain-
ing 5% fetal calf serum in 96-well plates. Cell viability of treated or
mock-treated cells was then analyzed for three to six consecutive days
by standard 3-(4,5 dimethylthiazolyl-2)-2,5-diphenyltetrazoleum-
bromide (MTT) assays (Roche Diagnostics, Almere, The Netherlands)
according to the manufacturer’s instructions.
Analysis of EGF Signaling
Cells were plated at day 0 at a density of 200,000 cells/well on six-well
plates. After an overnight incubation in serum-free medium, the cells
were stimulated with the indicated concentrations of EGF and were
harvested after the indicated periods of stimulation. Western blot analy-
sis was performed according to standard procedures. Quantity One
(Bio-Rad, Hercules, CA) software was used to quantify the signal inten-
sities and ratios between samples loaded on the same gel.
Ras Assay
TheRAS-binding domain of RAF1 fused to glutathione-S-transferase
and coupled to glutathione-sepharose was used as an affinity matrix for
activated RAS. The assay and subsequent Western blot analysis with
isoform-specific antibodies were performed exactly as described [21].
Reverse Transcription–Polymerase Chain Reaction
Cells were plated at day 0 at a density of 2.106 cells on 10 cm disks.
After overnight serum starvation, cells were stimulated with EGF and
reverse transcription–polymerase chain reaction was performed. RNA
was isolated using the TRIzol method, and complementary DNA
was synthesized by Superscript 2 (Invitrogen). The primers used were
as follows:
c-FOS forward: 5′-GTCTTCACCACCATGGAG-3′ and
c-FOS reverse: 5′-CCACCTTCTTGATGTCATC-3′,
GAPDH forward: 5′-CCTACCCAGCTCTGCTTCAC-3′, and
GAPDH reverse: 5′-GTGGGAATGAAGTTGGCACT-3′.
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Live Cell Imaging
Cells were seeded in a Lab-Tek Chambered no. 1.0 Borosilicate
Coverglass System (NalgeNunc International, Rochester, NY) and were
mounted on a Zeiss Axiovert 200M microscope (Carl Zeiss Micro-
imaging, Inc, Sliedrecht, The Netherlands) for live cell imaging under
5% CO2 at 37°C overnight. LysoTracker and Alexa 488–labeled EGF
(Invitrogen) were added to the wells, and images were captured every
10 seconds using a Photometrics CoolSNAP HQ charge-coupled de-
vice camera (Scientific, Tucson, AZ). Images were processed using
MetaMorph software (Universal Imaging, Downingtown, PA).
Immunofluorescence
Cells were grown on glass coverslips and either were stimulated with
EGFor were left unstimulated. Cells were fixed by the addition of 3.7%
formaldehyde to the culture medium for 10 minutes. Cells were then
permeabilized with 0.05% Triton X-100 in 1% PBS/BSA. Coverslips
were blocked in PBSwith 3%BSA for 1 hour. Anti-EGFR primary anti-
bodies were incubated at room temperature overnight. Secondary anti-
bodies were incubated for 1 hour at room temperature. Coverslips
were mounted using Vectashield with 4′,6-diamidino-2-phenylindole
(H-1200; Vector Labs, Burlingame, CA). Confocal images were ac-
quired using a Zeiss Meta Axiovert 200M confocal microscope (Carl
Zeiss, Microimaging, Inc), with a 40× 1.3 NA objective.
Tissue Microarray
A tissue microarray (TMA) was used to analyze the expression of
EGFR in colorectal tumors. The TMA was constructed as previously
described in detail [22]. In brief, samples from surgical resections of
55 patients with colorectal cancer with known KRAS mutation status
were selected for the TMA. For each sample, three different cylindrical
tissue cores were included in the TMA. Immunostaining was performed
using standard procedures. After incubating with 3% hydrogen per-
oxide, antigen retrieval was achieved by boiling in 10 mM citrate buffer
pH 6.0. Sections were blocked with 5% goat serum in TBS and incu-
bated with a rabbitα-EGFR (no. 2232; Cell Signaling Technology, Inc)
at 4°C overnight. The HRP-conjugated secondary antibody (DPVM-
55HRP; Immunologic, Duiven, the Netherlands) was detected with
3,3′-diaminobenzidine substrate (D4418; Sigma). Slides were counter-
stainedwith hematoxylin, were rinsedwithwater, dehydrated in ethanol,
cleared in xylene, and mounted on coverslips. The intensity and locali-
zation of EGFR staining and the percentage of positive cells were deter-
mined in each separate tissue core by two independent experienced
observers blinded to the cores’ identities. Staining intensity was scored
as follows: 0 = negative, 1 = weak, 2 = moderate, 3 = strong, 4 = very
strong. The percentages of positive cells were categorized as follows:
less than 1% as 0, 1% to 25% as 1, 25% to 50% as 2, and greater than
50% as 3. The staining coefficient was determined as the product of
the staining intensity and the percentage category, so with a maximum
score of 12. The EGFR antibody was validated byWestern blot analysis
using lysates of colorectal cancer cells and by immunohistochemistry on
formalin-fixed paraffin-embedded sections of normal human colon and
skin tissue. The staining and scoring procedures were independently
repeated by a third independent observer.
Statistical Analysis
Differences between the distinct treatment groups were evaluated
using the Student’s t test. Asterisks indicate statistical significance on
the basis of two-tailed analyses of the data sets. Differences with P <
.05 were considered statistically significant.
Results
Loss of Oncogenic KRAS Sensitizes Tumor Cells to
EGFR Inhibition
To assess the causal relationship between oncogenic KRAS and EGFR
independency, we made use of colorectal cancer cell lines with an acti-
vating mutation in KRAS (HCT116, DLD1, and CT26) and their
isogenic derivatives lacking oncogenic KRAS (HKH2, DKO4, and
CT26-KrasKD) [18,19]. Treatment of HCT116 and HKH2 cells with
the anti-EGFR antibody cetuximab or with the small-molecule inhibi-
tors gefitinib or erlotinib had no effect on parental (KRAS-mutant)
HCT116 cells but strongly reduced cell proliferation of KRAS–wild-
type HKH2 cells (Figure 1A). In addition, cetuximab only marginally
affected DLD1 cell proliferation but strongly inhibited DKO4 prolif-
eration (Figure 1B). Likewise, gefitinib had no effect on control
CT26 cells, but it suppressed cell proliferation on knockdown of the
mutant KRAS allele (Figure 1C ). Cetuximab could not be used in this
cell system because it does not recognize mouse EGFR. Gefitinib and
cetuximab also strongly reduced the proliferation of primary HIECs
[20] expressing wild-type KRAS. In contrast, neither gefitinib nor
cetuximab had any effect on the proliferation of freshly isolated colo-
rectal cancer stem cells with an activating mutation in KRAS (L145;
KRASD12; Figure 1D). In all these cases, the cells expressing mutant
KRAS were significantly more resistant to cell growth inhibition by
EGFR-targeting therapeutics than their isogenic KRAS-deleted/
suppressed counterparts (Figure W1). Cell death was not observed in
any of the previously mentioned experiments. These results suggest that
oncogenic KRAS is causally involved in reducing tumor cell dependency
on EGFR activity.
Oncogenic KRAS Reduces EGFR Control of
ERK Phosphorylation
The classic RAS/RAF/MEK/ERK pathway is one of the mitogenic
signaling pathways that is activated in response to EGFR stimulation.
We first assessed the contribution of EGFR activity to basal levels of
ERK phosphorylation. Treatment of cells lacking oncogenic KRAS
(HKH2, CT26-KrasKD, andHIEC) with either cetuximab or gefitinib
caused a strong decrease in the levels of basal ERK phosphorylation,
which corresponds with the observed reduction in cell proliferation
(Figures 2, A–C , andW1). In contrast, basal ERK phosphorylation was
unaffected in tumor cells expressing mutant KRAS (Figure 2, A–C ).
Thus, EGFR is a major determinant of basal ERK phosphorylation in
the absence but not in the presence of oncogenic KRAS.
EGF stimulation of HCT116 and HKH2 cells showed that the im-
mediate early response gene c-FOS was readily induced in HKH2
cells but not in HCT116 cells (Figure 3A). Oncogenic KRAS strongly
suppressed EGF-stimulated activation of ERK phosphorylation (Fig-
ure 3B). Because NRAS is an efficient activator of the ERK pathway,
we examined how oncogenic KRAS affected EGF stimulation of
(wild-type) NRAS activity. EGF strongly stimulated NRAS activity
in cells expressing wild type or no KRAS but not in the parental
cells expressing oncogenic KRAS (Figure 3C ). This suggests that the
desensitizing effect of oncogenic KRAS on EGF-stimulated ERK
pathway activation lies upstream of RAS activation. Indeed, receptor-
independent ERK pathway activation at the level of RAF by the phorbol
ester 12-O-tetradecanoylphorbol-13-acetate was unaffected, or even
more pronounced, in the presence of oncogenic KRAS (Figure 3D).
We conclude that oncogenic KRAS strongly reduces the impact of both
EGFR inhibition and activation on ERK phosphorylation.
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Next, we tested whether oncogenic KRAS selectively suppressed
EGF-stimulated ERK pathway activation or whether other pathways
were suppressed as well. Tyrosine-phosphorylated (activated) EGFR
binds the p85 subunit of PI3K, which results in the activation of
AKT. EGF stimulation of KRAS wild-type and mutant cells shows that
this pathway is also strongly suppressed by oncogenicKRAS (Figure 3E).
KRAS Alters EGFR Localization and Reduces EGF Binding
and Internalization
The previously mentioned results suggest that oncogenic KRAS desen-
sitizes cells to EGF at the level of the EGFR. Indeed, basal and EGF-
stimulated EGFR phosphorylation was strongly impaired in the presence
of oncogenic KRAS (Figure 4A). Live cell imaging using Alexa 488–
labeled EGF showed that HKH2 cells readily bound and internalized
EGF. A large proportion of EGF ended up in the lysosomes as expected
(Figure 4B). In contrast, whereas parental HCT116 cells express EGFR
(Figure 4A), they bound and internalized far less fluorescent EGF, al-
though some internalization could still be observed (Figure 4B). There-
fore, we examined the localization of the EGFR by immunofluorescence
analysis. Strikingly, in parental HCT116 cells, most of the EGFR were
found in intracellular vesicles (Figure 4C), and their distribution did not
change after receptor stimulation (Figure 4D). In HKH2 cells, however,
the EGFR predominantly localized to the plasmamembrane (Figure 4C)
and was internalized after stimulation with EGF (Figure 4, B and D), or
after re-expression of KRASG13D (Figure W2). In line with these results,
prolonged stimulation with EGF, or with cetuximab, caused down-
regulation of the EGFR in cells expressing wild-type KRAS but not in cell
expressing mutant KRAS (Figure 4E). Also, in the CT26 cell system, we
found that suppression of the oncogenic KrasD12 allele restored plasma
membrane localization of the EGFR (Figure 5A). Stimulation of CT26
cells did not affect intracellular localization of the EGFR. However,
stimulation ofCT26-KrasKDcells causedEGFRclustering and internali-
zation, similar to what was observed in HKH2 cells (Figure 5A). In line
with these results, CT26-KrasKD cells, but not CT26 cells, efficiently
internalized fluorescent EGF (Figure 5B).
Next, we tested whether the relationship between oncogenic KRAS
and altered EGFR localization was also observed in human colorectal
tumors. To this end, we analyzed EGFR localization in a panel of 55
Figure 1. Deletion of oncogenic KRAS sensitizes colorectal tumor cells to EGFR inhibition. (A) HCT116 andHKH2 cellswere seeded in 96-well
plates and were treated with cetuximab (20 μg/ml), erlotinib (5 μM), or gefitinib (2 μM) for four consecutive days in triplicate. Mitochondrial
activitywas determined byMTT assays. (B) The experimentwas performed as in panel A, using cetuximab (20 μg/ml) to treat DLD1andDKO4
cells. (C) The experiment was performed as in panel A, using gefitinib (2 μM) to treat CT26 cells expressing luciferase-targeting shRNA (CT26)
and CT26 cells in which endogenous KrasD12 is stably suppressed by RNAi [19]. (D) The experiment was performed as in panel A, using
cetuximab (20 μg/ml) or gefitinib (2 μM) on L145 cells. L145 cells were freshly established from a liver metastasis harboring a KRASD12
mutation. Primary human epithelial cells (HIEC [20]) express only wild-type KRAS. *Statically significant differences, P < .05.
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Figure 2. EGFR activity is required for maintenance of ERK phosphorylation in wild-type KRAS cells but not inmutant KRAS cells. (A) HCT116
cells and HKH2 cells were treated overnight with the indicated EGFR inhibitors, and phosphorylated and total ERK levels were assessed
by Western blot analysis. Bar diagrams represent means and SEM of three independent experiments. (B) As in panel A, using CT26 cells
expressing luciferase-targeting shRNA (CT26) and CT26-KrasKD. (C) As in panel A, using L145 cells and HIEC. *Statically significant differ-
ences, P < .05.
Figure 3. Oncogenic KRAS suppresses EGFR signaling. (A) Serum-starved HCT116 and HKH2 cells were stimulated with 20 ng/ml EGF for 0,
30, and 60minutes. c-FOSmessenger RNA levelswere determined using reverse transcription–polymerase chain reaction. (B) Serum-starved
HCT116, DLD1, and CT26 cells and their isogenic derivatives lacking oncogenic KRAS (HKH2, DKO4, and CT26-KrasKD) were stimulated
with 20 ng/ml EGF for 5minutes. The levels of phosphorylated and total ERKweredetermined byWesternblot analysis. (C) Cellswere cultured
and stimulated as in panel B. Ras activity assays were performed using the Ras-binding domain (RBD) of Raf1 fused to glutathione-S -
transferase immobilizedonglutathione-sepharose. Lysates andRBD-Raf1–bound proteinswere analyzed for thepresence ofNRASandKRAS
by Western blot analysis. (D) Cells were cultured as previously mentioned and stimulated with the phorbol ester 12-O-tetradecanoylphorbol-
13-acetate (5 nM) for 5minutes. The levels of phosphorylated and total ERKwere determined byWestern blot analysis. (E) Cellswere cultured
as previously mentioned and stimulated with 20 ng/ml EGF for 5 minutes. The levels of phosphorylated and total AKT were determined by
Western blot analysis.
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colorectal carcinomas with known KRASmutation status using antibody
no. 2232 from Cell Signaling Technology (Figures 6 and W3). Of
these tumors, 12 showed normal basolateral EGFR staining, 32 showed
diffuse staining throughout the tumor cells, and 11 were negative (Fig-
ure 6, A and B). In this panel, 16 tumors had an activating mutation in
KRAS. Strikingly, only 1 of these tumors displayed normal basolateral
staining, 10 displayed diffuse staining, and 5 had lost EGFR staining
altogether (Figure 6B). A χ 2 test revealed that the unequal distribution
of KRAS mutations in tumors with basolateral EGFR staining (1/12)
versus tumors with either negative or diffuse staining (15/43) showed a
trend toward statistical significance (P = .073). This result suggests that
KRASmutationsmay be associatedwith loss of normal basolateral EGFR
localization in human colorectal tumors, which could influence the re-
sponsiveness of these tumors to EGFR ligands.
ROK Inhibition Restores EGFR Plasma Membrane
Localization and EGF Signaling but Not EGFR Dependency
The previously mentioned results suggest that desensitization
of HCT116 and CT26 cells to EGF could be due to the loss of EGFR
localization from the plasma membrane.We reasoned that inhibition of
KRAS signaling could restore EGFR plasma membrane localization.
Therefore, we treated HCT116 cells with inhibitors targeting MEK,
Rac, PI3K, and ROK and evaluated the response of these cells to EGF.
PI3K or Rac inhibition completely abolished AKT (but not ERK)
phosphorylation, but it did not sensitize the tumor cells to EGF. Like-
wise, MEK inhibition abolished ERK (but not AKT) phosphorylation,
but it did not sensitize the tumor cells to EGF. However, inhibition of
ROK sensitized cells to EGF-stimulated phosphorylation of ERK1/2
and AKT, albeit not as efficiently as after deletion of mutant KRAS
(Figure 7,A andB). ROK inhibition also restored EGF-induced tyrosine
phosphorylation of the EGFR (Figure 7C). Furthermore, immunoflu-
orescence analysis showed that the sensitization of HCT116 cells to
EGF by ROK inhibition was accompanied by restoration of EGFR
localization to the plasma membrane (Figure 7D). Next, we tested
whether restoration of EGF signaling in ROK-inhibited cells would
be accompanied by a newly acquired dependency on EGFR signaling.
To this end, HCT116 cells were treated with cetuximab or gefitinib and
the ROK inhibitor Y27632, either alone or in combination. Figure 7E
shows that the proliferation of HCT116 cells was not significantly
affected by treatment with the drugs, either alone or in combination,
Figure 4. Aberrant EGFR localization and reduced EGF internalization in HCT116 cells. (A) Serum-starved HCT116 and HKH2 cells were stim-
ulated with 20 ng/ml EGF for 0 or 5 minutes. Total and phosphorylated EGFR levels were determined by Western blot analysis. (B) Serum-
starved HCT116 and HKH2 cells were stimulatedwith Alexa 488–conjugated EGF (30 ng/ml; 20minutes) in the presence of LysoTracker. The
uptake of fluorescent EGF and its trafficking to lysosomeswere analyzed by live cell imaging. Final images are shown. (C) HCT116 cells were
grown on glass coverslips, and EGFR localization was studied by immunofluorescence analysis. (D) Serum-starved HCT116 cells were stim-
ulated with 20 ng/ml EGF (0 or 20 minutes). EGFR (green) and F-actin (red) distributions were then analyzed by immunofluorescence.
(E) HCT116 cells were incubated overnight with EGF (20 ng/ml) or cetuximab (20 μg/ml) under serum-free conditions. EGFR and actin levels
were determined by Western blot analysis.
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although both the ROK and EGFR inhibitors were effective in inducing
and suppressing EGFR-dependent ERK phosphorylation, respectively.
Next, we tested the effect of ROK inhibition on EGF signaling in CT26
cells. In line with the results previously mentioned, ROK inhibition
by Y27632 promoted ERK phosphorylation by EGF (Figure 7F ) and
restored EGFR plasma membrane localization in CT26 cells (Fig-
ure 7G ). Also, in this cell system, Y27632 did not restore tumor cell
sensitivity to EGFR inhibition by gefitinib (Figure 7H ). Taken together,
the results suggest that ROK inhibition restores EGFR plasma mem-
brane localization and EGF signaling, but it does not restore tumor cell
dependency on EGFR activity.
Discussion
The association of KRASmutations with resistance to EGFR inhibitors
has been demonstrated in a large number of clinical studies, both in
patients with colorectal cancer and lung cancer [14]. Our study shows
that oncogenic KRAS is causally involved in mediating resistance to
EGFR-targeted therapeutics. Constitutive signaling by oncogenicKRAS
may reduce the requirement for EGFR activity as an upstream RAS
activator. Although we did not observe reduced basal phosphorylation
of the ERK or AKT protein kinases after deletion of oncogenic KRAS,
maintenance of the activity of these pathways became dependent
on EGFR signaling. This lends support to the hypothesis that KRAS
Figure 5. Aberrant EGFR localization and reduced EGF internalization in CT26 cells. (A) CT26 control cells and CT26-KrasKD cellswere grown
on glass coverslips. Cells were serum-starved overnight and were subsequently stimulated with 20 ng/ml EGF for 20 minutes. Coverslips
were then stained for EGFR and were analyzed by immunofluorescence. (B) CT26 and CT26-KrasKD cells were stimulated with Alexa 488–
conjugated EGF (30 ng/ml; 20 minutes). Cells were then fixed and analyzed for the uptake of fluorescent EGF by confocal microscopy.
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renders cells less dependent on the EGFR for maintaining the activity of
these critical signaling pathways, albeit at relatively low basal levels.
Oncogenic KRAS desensitized cells not only to EGFR inhibition but
also to EGFR activation by altering its intracellular localization. EGFR
localization, internalization, and trafficking are controlled by a complex
network of signaling molecules [23,24]. After EGF stimulation, the
EGFR is downregulated through ubiquitination and lysosomal degra-
dation. Alternatively, internalized EGFR can recycle back to the plasma
membrane or can be retained inside the cell. The reduction in cell sur-
face EGFR in KRAS mutant cells limits its availability to EGF and to
EGFR-targeting antibodies. We have so far not been able to identify
the KRAS effector pathway(s) that cause(s) altered EGFR localization.
Although suppression of ROK signaling partially restored EGFR locali-
zation to the plasma membrane and EGF responsiveness, the activity
of RhoA or ROK was reduced rather than elevated in mutant KRAS
cells when compared with wild-type KRAS cells (W.J.v.H. and M.d.B.,
unpublished observations). This suggests that basal ROK activity is
required for EGFR internalization but that mutant KRAS does not
stimulate this pathway to accelerate EGFR internalization.
RNA interference (ERK1, ERK2, ERK1+ERK2, ARAF,BRAF,CRAF,
RalA, and RalB) and inhibitor studies (sorafenib, U0126, LY294002,
and Rac1) failed to implicate these classic KRAS effector pathways
in desensitizing HCT116 and/or CT26 cells to EGF (W.J.v.H., un-
published observations). Possibly, either a combination of effectors
or subtle alterations in effector protein activity or localization are re-
quired for altering EGFR localization rather than robust changes in
expression levels or activity.
From clinical studies, it has become clear that wild-type BRAF is re-
quired for response to EGFR therapy in metastatic colorectal cancer
[25]. In addition, the Raf/vascular endothelial growth factor receptor
inhibitor sorafenib has been used in combination with EGFR inhibitors
in the treatment of several solid malignancies [26]. The rationale for
this was to simultaneously target the tumor cells (EGFR inhibition)
and the vasculature (vascular endothelial growth factor receptor inhibi-
tion).However, sorafenib is also a potent RAF kinase inhibitor, and RAF
kinases are critical KRAS-activated signal transducers in lung cancer cells
[27]. Therefore, it is possible that sorafenib could sensitize colorectal
tumor cells to EGFR inhibition by suppressing KRAS/RAF signaling.
Our in vitro results do not support such a simple mechanism because
neither sorafenib treatment nor RNAi-mediated suppression of RAF
kinases could restore tumor cell sensitivity to EGF or EGFR inhibition
(W.J.v.H., unpublished observations). This suggests that other RAS ef-
fector pathways and/or a combination of effector pathways mediate
KRAS-dependent resistance to EGFR inhibition.
Taken together, mutant KRAS causes intracellular retention of the
EGFR, which dampens the tumor cell response to EGF. Interestingly,
high levels of EGFR ligands predict tumor responsiveness to cetuximab
but only in tumors with wild-type KRAS [15,16]. Our results suggest
that in mutant KRAS tumors, the EGFR is likely to be a relatively in-
efficient signal transducer because of its absence from the basolateral
membrane. We propose that oncogenic KRAS fixes the activation state
of its effector pathways at levels that are relatively low when compared
with those achieved after EGF stimulation of KRAS wild-type cells but
are high enough to sustain cell proliferation and viability.
EGFR protein levels, as determined by immunohistochemistry, are
not associated with the response of colorectal tumors to cetuximab
[28,29]. Our results show that a minor population of human colorec-
tal cancer tumors with wild-type KRAS shows proper polarized basal/
basolateral localization of the EGFR, similar to what is observed in
normal colon tissue. Interestingly, the effect of EGFR activation or
inhibition on colorectal cancer cell proliferation was previously shown
to be dependent on cell polarity: Only when stimulated or inhibited
at the basolateral side does modulation of EGFR activity affect
tumor cell proliferation [30]. Possibly, polarized EGFR staining, rather
than total protein levels, may identify a subset of wild-type KRAS
tumors that respond to EGFR-targeted therapy. This hypothesis should
Figure 6. Aberrant localization of the EGFR in colorectal tumors expressing oncogenic KRAS. A TMA containing a panel of colorectal tumors
with known KRAS mutation status was used to study EGFR localization. (A) We distinguished three types of staining. 1) Basolateral and
membranous; examples are shown in the left upper and left lower images. 2) Negative; an example is shown in the right upper image.
3) Diffuse throughout the tumor cells with negative membrane staining; an example is shown in the right lower image. (B) The staining co-
efficientwas determined as the product of the staining intensity on a 0 to 4 scale (with 0=negative, 1=weak, 2=moderate, 3= strong, 4=
very strong) and the percentage positive cells on a 0 to 3 scale (with <1%=0, 1%-25%= 1, 25%-50%= 2,>50%=3). The staining scores
for all tumors (with a maximum score of 12) were then plotted. The tumors with activating mutations in KRAS are circled in red.
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be tested in the tumors of cetuximab-treated cohorts of colorectal can-
cer patients.
Restoration of proper EGFR localization and signaling in colorectal
cancer cells with oncogenic KRAS is possible (by ROK inhibition),
but this does not restore tumor cell dependency on EGFR signaling.
EGFR unresponsiveness is therefore uncoupled from EGFR indepen-
dency. The results suggest that the combination of ROK inhibitors with
EGFR inhibitors does not seem to be a logical combination strategy to
pursue in the clinic at the moment. Identification of (the combination
of) KRAS-activated effector pathways that mediate EGFR indepen-
dency remains a major challenge for future studies.
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Figure W2. KRASG13D expression causes loss of EGFRmembrane lo-
calization inHKH2 cells. HKH2-KRASG13D cells and control-transfected
HKH2 cells were analyzed by Western blot analysis for the expres-
sion of KRAS (upper panel) [1], and for EGFR localization by immuno-
fluorescence analysis using rabbit antihuman EGFR (2232; Cell
Signaling Technology; lower panel).
Figure W1. Deletion of oncogenic KRAS allows growth inhibition by
EGFR-targeting therapeutics. Cells were treated for 4 days with the
indicated compounds (Figure 1). MTT values of inhibitor-treated cells
were then plotted as percentage of untreated controls. The effect of
EGFR inhibition in KRAS mutant cells was minimal (20% at most),
whereas KRAS deletion/suppression allowed growth inhibition in
all cases. All differences between isogenic wild-type and mutant
KRAS cell lines were statistically significant (*P < .05).
Figure W3. Validation of anti-EGFR antibody no. 2232. (A) Western blot analysis of 50 μg of a HCT116 cell lysate. (B) Immunohistochemistry
of skin and normal colon showing membrane (skin) and polarized basal (colon) staining.
